Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xykaa Extend is an extended-release oral tablet formulation of paracetamol (acetaminophen) developed by Troikaa Parenterals. It utilizes Troikaa's proprietary Duo Phase Technology, which splits the paracetamol dose into an immediate-release component for rapid onset of action and a sustained-release component to maintain therapeutic drug levels over an extended period. Xykaa Extend is approved and marketed in India for the management of mild-to-moderate pain (such as headache, toothache, backache, and joint pain) and the reduction of fever (pyrexia). It acts primarily in the central nervous system to inhibit prostaglandin synthesis and modulate the hypothalamic heat-regulating center.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xykaa Extend.